Ftse Mib
34.603,61
-0,64%
DAX
18.726,76
-0,21%
S&P 500
5.321,41
0,25%
NASDAQ
16.832,62
0,22%
Bitcoin
70.136,89
0,01%

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ LAVA Therapeutics NV (LVTX) LAVA Therapeutics NV (LVTX) Notizie

LVTX

LAVA Therapeutics NV (LVTX)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LVTX
DataOraFonteTitoloSimboloCompagnia
21/05/202422:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:LVTXLAVA Therapeutics NV
25/01/202414:07Dow Jones NewsLava Therapeutics Shares Rise as Drug Set for Test With Merck's KeytrudaNASDAQ:LVTXLAVA Therapeutics NV
06/09/202313:11GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:LVTXLAVA Therapeutics NV
22/08/202313:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
14/08/202313:00GlobeNewswire Inc.LAVA Therapeutics to Participate in the H.C. Wainwright Immune Cell Engager Virtual ConferenceNASDAQ:LVTXLAVA Therapeutics NV
15/06/202322:51Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:LVTXLAVA Therapeutics NV
14/06/202315:00GlobeNewswire Inc.LAVA Therapeutics Provides Updates on Clinical Programs and Extends the Cash RunwayNASDAQ:LVTXLAVA Therapeutics NV
08/06/202313:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports First Quarter 2023 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
06/06/202312:02Edgar (US Regulatory)Amended Statement of Beneficial Ownership (sc 13d/a)NASDAQ:LVTXLAVA Therapeutics NV
06/06/202300:31Edgar (US Regulatory)Report of Proposed Sale of Securities (144)NASDAQ:LVTXLAVA Therapeutics NV
02/06/202301:38Dow Jones NewsStocks to Watch: Lululemon, Lava Therapeutics, Tilly's, OncorusNASDAQ:LVTXLAVA Therapeutics NV
01/06/202322:20GlobeNewswire Inc.LAVA Therapeutics Announces Selection by Janssen of Lead Gamma-Delta T-Cell Engager Bispecific Antibody to Move Toward Clinical DevelopmentNASDAQ:LVTXLAVA Therapeutics NV
01/06/202314:09GlobeNewswire Inc.LAVA Therapeutics to Participate in the Jefferies Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
30/05/202323:28GlobeNewswire Inc.LAVA Announces Annual Meeting of ShareholdersNASDAQ:LVTXLAVA Therapeutics NV
11/04/202313:00GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2022 Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
09/03/202314:05GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Christy J. Oliger to its Board of DirectorsNASDAQ:LVTXLAVA Therapeutics NV
16/02/202313:00GlobeNewswire Inc.LAVA Therapeutics Announces Initial Data from the Ongoing Phase 1/2a Clinical Trial of LAVA-1207 in Therapy Refractory mCRPC at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
09/02/202313:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 2023 SVB Securities Global Biopharma ConferenceNASDAQ:LVTXLAVA Therapeutics NV
06/02/202313:00GlobeNewswire Inc.LAVA Therapeutics Announces the Appointment of Dr. Charles Morris as Chief Medical OfficerNASDAQ:LVTXLAVA Therapeutics NV
23/01/202313:00GlobeNewswire Inc.LAVA Therapeutics to Present LAVA-1207 Clinical Data at the 2023 ASCO GU SymposiumNASDAQ:LVTXLAVA Therapeutics NV
06/01/202319:07GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of New Directors to the BoardNASDAQ:LVTXLAVA Therapeutics NV
03/01/202313:00GlobeNewswire Inc.LAVA Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
23/12/202222:02Edgar (US Regulatory)Amended Annual and Transition Report (foreign Private Issuer) (20-f/a)NASDAQ:LVTXLAVA Therapeutics NV
12/12/202212:25TipRanksH.C. Wainwright Keeps Their Buy Rating on LAVA Therapeutics (LVTX)NASDAQ:LVTXLAVA Therapeutics NV
10/12/202216:00GlobeNewswire Inc.LAVA Therapeutics Announces Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LVTXLAVA Therapeutics NV
16/11/202222:05GlobeNewswire Inc.LAVA Therapeutics Provides Business Update and Reports Third Quarter Financial ResultsNASDAQ:LVTXLAVA Therapeutics NV
03/11/202221:05GlobeNewswire Inc.LAVA Therapeutics to Present at the Jefferies London Healthcare ConferenceNASDAQ:LVTXLAVA Therapeutics NV
03/11/202214:00GlobeNewswire Inc.LAVA Therapeutics to Present Updated Data from the Phase 1/2a Clinical Trial of LAVA-051 at the 64th American Society of Hematology (ASH) Annual Meeting and ExpositionNASDAQ:LVTXLAVA Therapeutics NV
01/11/202212:00GlobeNewswire Inc.LAVA Therapeutics Announces Appointment of Fred M. Powell as Chief Financial OfficerNASDAQ:LVTXLAVA Therapeutics NV
07/10/202217:00GlobeNewswire Inc.LAVA Therapeutics to Present On-Mechanism Pharmacodynamics Data from the Phase 1/2a Clinical Trial of LAVA-051 at the Society for Immunotherapy of Cancer (SITC) 2022 Annual MeetingNASDAQ:LVTXLAVA Therapeutics NV
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:LVTX

La tua Cronologia

CSE
BEV
BevCanna Enterprises
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' CLICCA QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network